The antibody profile in patients with SSc is crucial for predicting the current state of ILD: antibodies against topoisomerase I (ATA; also known as anti-Scl-70) [11,12] are primarily associated with the progression of pulmonary fibrosis, while antibodies against RNA polymerase III (anti-RNAP III) are linked to a higher risk of pulmonary hypertension and cardiac complications [3]. Here, ATM is linked to pulmonary fibrosis.